Prospective Real-Life Multicenter Study of Tildrakizumab 200 Mg for Moderate-to-Severe Psoriasis: Who Is the Ideal Patient?. Dermatol Pract Concept 2024, 14 (4), e2024284. https://doi.org/10.5826/dpc.1404a284.